Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose.

Kaaijk, Patricia; Nicolaie, M Alina; van Rooijen, Debbie; van Houten, Marianne A; van der Klis, Fiona R; Buisman, Anne-Marie; van Binnendijk, Rob S

Kaaijk, Patricia; Nicolaie, M Alina; van Rooijen, Debbie; van Houten, Marianne A; van der Klis, Fiona R; Buisman, Anne-Marie; van Binnendijk, Rob S.

Afiliação

Kaaijk P; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Nicolaie MA; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
van Rooijen D; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
van Houten MA; Spaarne Gasthuis Academy, Hoofddorp, the Netherlands.
van der Klis FR; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Buisman AM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
van Binnendijk RS; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Open Forum Infect Dis ; 7(11): ofaa505, 2020 Nov.

Article em En | MEDLINE | ID: mdl-33269296

ABSTRACT

ABSTRACT

BACKGROUND:

Breakthrough infections of measles and mumps have raised concerns about the duration of vaccine-induced immunity, which might be improved by a third dose of measles-mumps-rubella vaccine (MMR3).

METHODS:

Here we compared (IgG) antibody levels against measles, mumps, and rubella in blood samples of 9-year-old children and young adults (18-25 years) following MMR2 and MMR3, respectively.

RESULTS:

We found that, in addition to antibody boosting for all 3 vaccine components, MMR3 resulted in lower antibody decay rates than MMR2; the declines were most prominent for mumps and rubella.